Defiance Autism Impact ETF (ASD)
| Assets | $1.35M |
| Expense Ratio | 0.79% |
| PE Ratio | 14.90 |
| Shares Out | 50,000 |
| Dividend (ttm) | $0.01 |
| Dividend Yield | 0.03% |
| Ex-Dividend Date | Sep 23, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 0.45% |
| Volume | 328 |
| Open | 26.42 |
| Previous Close | 26.40 |
| Day's Range | 26.42 - 26.42 |
| 52-Week Low | 24.59 |
| 52-Week High | 28.52 |
| Beta | n/a |
| Holdings | 41 |
| Inception Date | Jun 1, 2026 |
About ASD
Fund Home PageThe Defiance Autism Impact ETF (ASD) is an exchange-traded fund that is based on the VettaFi Autism Impact index. The fund tracks an equal-weighted index of companies from developed markets supporting individuals on the autism spectrum and broader community. The fund donates profits to organizations focused on autism care, research, and access to resources. ASD was launched on Jun 1, 2026 and is issued by Defiance.
Top 10 Holdings
28.64% of assets| Name | Symbol | Weight |
|---|---|---|
| Revvity, Inc. | RVTY | 3.31% |
| Repligen Corporation | RGEN | 2.91% |
| Teva Pharmaceutical Industries Limited | TEVA | 2.88% |
| Sumitomo Pharma Co., Ltd. | 4506 | 2.84% |
| Medicover AB (publ) | MCOV.B | 2.81% |
| Graham Holdings Company | GHC | 2.80% |
| Eli Lilly and Company | LLY | 2.80% |
| Otsuka Holdings Co., Ltd. | 4578 | 2.76% |
| Pearson plc | PSON | 2.76% |
| Takeda Pharmaceutical Company Limited | 4502 | 2.76% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 23, 2026 | $0.00199 | Sep 24, 2026 |
| Jun 24, 2026 | $0.00597 | Jun 25, 2026 |
Performance
News
What Advisors Need to Know About the First Autism ETF
As autism diagnoses rise, and research, regulation, and public awareness reshape the landscape, a broader neurodiversity care ecosystem is taking shape.
How to Invest in the Growing Autism Care Economy
The autism care economy is expanding across healthcare, technology, education, and behavioral services. As a result, investors are beginning to look at the companies serving it through a broader inves...
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
SAN FRANCISCO and BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering ...
Defiance Launches the First Autism-Impact ETF (Ticker: ASD), Donating Profits to Autism Causes *
MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Autism Impact ETF (Ticker: ASD) , the first exchange-traded fund designed to provide targeted exposure...